Search
Fluconazole
go.drugbank.com/drugs/DB00196ApprovedInvestigationalFluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. … It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole].
Products: FLUCONAZOLEN CLORURO DE SODIO INYECCIÓNLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalto be the primary pruritogens. … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalAs a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. … Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua.
Categories: Sex Hormones and Modulators of the Genital System, Progesterone Receptor ModulatorsAlvimopan
go.drugbank.com/drugs/DB06274ApprovedInvestigationalIt is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.
Categories: Peripheral Opioid Receptor AntagonistsDexlansoprazole
go.drugbank.com/drugs/DB05351Approvedrelease system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing. … Dexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers.
Products: DEXOPRAL ® 60 CAPSULA DE LIBERACIÓN RETARDADA, DEXOPRAL ® 30 CAPSULA DE LIBERACIÓN RETARDADAInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia … [L39593] It is marketed under the trade name Leqvio.
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIt is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Synonyms: E-EPATofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalIt is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. … Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Products: XELJANZ® XR 11 MG TABLETAS DE LIBERACIÓN MODIFICADALinezolid
go.drugbank.com/drugs/DB00601ApprovedInvestigational[L32965] Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050 … Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLithium carbonate
go.drugbank.com/drugs/DB14509ApprovedInvestigationalLithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. … Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome